COMP <GO>
WAT vs ABBV // REVENUE GROWTH (YOY)
Waters Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: WAT 6
— ABBV 9
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $462.72 (-3.61%) • MKT CAP: $47.17B
revenue-growth
7.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WAT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WAT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 70.20% | -10.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.80% | 29.00% | -12.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 51.5x | 33.3x | +18.20 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.08% | 3.47% | -2.39 | ABBV | /fcf-yield <GO> |
| Operating Margin | 25.40% | 24.60% | +0.80 | WAT | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 6.90% | +13.40 | WAT | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 7.00% | 8.60% | -1.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.49 | 5.33 | +10.16 | WAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | WAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | WAT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 72.8 | -12.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.15 | -0.13 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 68.3x | 113.1x | -44.80 | WAT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $47.17B | $513.86B | -$466.69B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WAT REV | ABBV REV | WAT GROSS % | ABBV GROSS % | WAT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.17B | $61.16B | 59.3% | 70.2% | $510.1M | $17.82B |
| FY 2024 | $2.96B | $56.33B | 59.4% | 70.0% | $629.0M | $17.83B |
| FY 2023 | $2.96B | $54.32B | 44.0% | 44.0% | $469.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WAT // BETA 1.02
ABBV // BETA 1.15